ACIU

AC Immune Ltd (Ticker: ACIU) is a leading clinical-stage biopharmaceutical firm headquartered in Lausanne, Switzerland, focused on pioneering therapies and diagnostics for neurodegenerative diseases linked to protein misfolding, including Alzheimer's disease. Leveraging its proprietary platforms, the company is actively engaged in the discovery and development of innovative treatments aimed at modifying disease progression and enhancing patients' quality of life. With a robust pipeline of candidates, AC Immune is positioned at the forefront of addressing some of the most pressing challenges in neurology, making it a compelling prospect for institutional investors seeking exposure to the biopharmaceutical sector.